NCT00292253View on ClinicalTrials.gov

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

1,883

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
Multiple Sclerosis, Relapsing-remitting
Interventions
DEVICE

Rebif® via Rebiject™Mini

Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.

DEVICE

Rebif® via manual injections

Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
collaborator

Merck Serono International SA

INDUSTRY

lead

EMD Serono

INDUSTRY

NCT00292253 - Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects | Biotech Hunter | Biotech Hunter